The BIO 2011 conference is just around the corner, and Washington DC prepares for some 15,000 delegates from 65 different countries to descend upon its limits, which means it’s almost time for this year’s Worldview Regional Bio-Innovation Scorecard. This morning, the Biotechnology Industry Organization (BIO) hosted a press conference in DC to provide some highlights on the upcoming conference and to leak a few details of what this year’s scorecard would capture.
Over the last three years, Scientific American has partnered with BIO to produce a global ranking of countries in several areas related to innovation in the biotechnology sector (find a link to the 2009 results here). Jeremy Abbate, Director of Global Media Publishing at Scientific American, explained that as certain countries around the world are catching up to the US in terms of their production of innovative products, the biotechnology sector is becoming exceedingly global, and that a publication like Scientific American Worldview: A Global Perspective is needed to broadly document new trends and developments.
The essence of Worldview is to promote dialogue on what elements drive innovation, and to answer some pertinent questions: what characteristics or attributes make a country innovative? what makes a person innovative? Another goal is to identify individuals that are forces within the sector — those influential characters that are making the difference — the so called “heroes of science and finance”. Abbate iterated that although Worldview does not have all of the answers yet, it has collected massive quantities of data on the biotech sector in pursuit of them, and the scorecard is its “pièce de résistance”.
So what can you expect to see in 2011′s Worldview Regional Bio-Innovation Scorecard?
Last year’s separated the hype from the hope with a focus on China. This year China will be under the spotlight again, but this time along with the first three of the BRICs countries, including Brazil, Russia, and India. The scorecard will look closely at what these countries have to offer in terms of their capacity to innovate, their scientific output, and what capital they have available for investment. A special emphasis will be placed on the bio-innovation workforce they have to deploy across the biotechnology, medical device, and pharmaceutical industries.
The 2011 scorecard will point to the world’s fastest growing drug markets, take a deep dive on Africa and Australia, and present some analysis on innovative products, what countries pay to produce them, and how price has been affecting output. Russia’s Pharma 2020 initiative also comes into play. Will Russia be the manufacturing powerhouse that some hope it will be? During the briefing, Nikolay Savchuck, passed industry representative to the Russian government’s Pharma 2020 initiative, joked with the press that, unlike China, Russia has been all hope and no hype; perhaps it is Russia’s turn to deliver.
Making its debut to the scorecard will be the “Worldview Biotech Movers”. This section will highlight three game changers in the biotech sector and what they are doing to lubricate the cogs of innovation. This year expect to become a little more familiar with India’s Kiran Shaw of Biocon, China’s Ge Li of WuXi AppTech, and one other influential individual from Brazil. Although not always “friendly” to innovation on a global scale, these people march to their own drum and thrive on a regional basis.
The movers section of the scorecard touches on Abbate’s question — what makes a person innovative? Unlike definable elements that contribute to a country’s capacity to innovate, like intellectual property, a sound regulatory environment, science-minded policy, R&D investment, and so forth, the qualities of a great human innovator are much more nebulous. Ultimately, a country’s capacity to innovate may rely to a large degree on people. The work behind Worldview may in time bring some tangibility to this subject.
Snapshot from Canada
Cate McCready, VP of External Relations at BIOTECanada, spoke to the press and provided a snapshot of the Canadian biotechnology sector. In 2008, the Canadian government began an industrial analysis of biotechnology in the country which indicates the sector is contributing in the realm of $86 billion annually to Canada’s GDP. Although this figure is primarily driven by healthcare, McCready notes that there has recently been a divergence to other biotechnology industries, namely agricultural biotechnology, which is growing rapidly. Canada currently has 600 biotechnology companies operating within its borders, from “coast-to-coast-to-coast”, as McCready puts it. Be sure to check out Canada Cafe at the conference later this month.
A Few Highlights
So which countries will win accolades? The scorecard preview didn’t give up many hard stats, and leaves much to the imagination, so you’ll have to wait until it’s unveiled at BIO on June 29th.
Officially in, however, Denmark will take no. 1 for biotech patenting, while New Zealand proves to have the greatest number of PhD candidates per capita.